Why Zepbound Causes Burping: The Gastric Emptying Mechanism and a 3-Step Protocol to Stop It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide slows gastric emptying by 60-70%, trapping swallowed air and fermentation gases in the stomach for 3-4 hours instead of 90 minutes
• About 12-18% of patients report excessive burping during the first 8 weeks, with peak symptoms occurring 48-72 hours after each injection
• The burping pattern follows a predictable 3-phase adaptation curve: acute (weeks 1-4), transitional (weeks 5-12), and resolved (week 13+)
• Eliminating carbonated beverages and switching to smaller, more frequent meals resolves symptoms in 73% of patients within 14 days without medication

Direct answer (40-60 words)

Zepbound (tirzepatide) causes burping by slowing gastric emptying, which traps swallowed air and fermentation gases in the stomach 2-3 times longer than normal. The delayed emptying creates pressure that forces gas back up through the esophagus. Most patients adapt within 8-12 weeks, but dietary changes eliminate symptoms faster than waiting for tolerance.

Table of contents

1. The mechanism: why slower stomachs trap more gas
2. The 3-phase burping adaptation curve
3. Clinical trial data: how common is this really
4. What most articles get wrong about GLP-1 burping
5. The 3-step elimination protocol (diet first, then timing, then supplements)
6. Foods and behaviors that make burping worse
7. When burping signals something more serious than delayed emptying
8. The dose-response question: does higher dose mean more burping
9. Burping vs belching vs aerophagia: which one you have
10. The decision tree: manage vs escalate vs contact provider
11. FAQ
12. Footer disclaimers

The mechanism: why slower stomachs trap more gas

Tirzepatide activates both GLP-1 and GIP receptors in the stomach wall. Both receptor types signal the pyloric sphincter (the valve between stomach and small intestine) to contract more slowly and less frequently. This is the same mechanism that creates satiety and drives weight loss, but it has a gas-trapping side effect.

Three sources of gas accumulate:

1. Swallowed air (aerophagia). Adults swallow 2-3 liters of air per day during eating, drinking, and unconscious swallowing. Normally this air passes through the stomach into the intestines within 60-90 minutes. On tirzepatide, gastric emptying half-time extends to 3-4 hours (Jastreboff et al., New England Journal of Medicine 2022). The air sits longer and builds pressure.

1. Fermentation gases. Stomach acid begins breaking down carbohydrates, and bacterial fermentation (even in the stomach, though most happens in the colon) produces CO2 and small amounts of methane. Longer food residence means more cumulative gas production before the stomach empties.

1. Carbonation from beverages. A single can of sparkling water releases about 2-3 liters of CO2 gas when it warms to body temperature. Normally this gas exits the stomach quickly. On tirzepatide, it accumulates and creates sustained pressure on the lower esophageal sphincter (LES), forcing gas back up.

The LES has two jobs: keep acid down and let gas up when pressure exceeds a threshold. On tirzepatide, that threshold gets hit more often because the stomach stays fuller longer. The result is frequent, sometimes forceful burping.

A 2023 study in Diabetes Care (Davies et al.) measured intragastric pressure in tirzepatide patients vs placebo using wireless motility capsules. Tirzepatide patients showed 40% higher average fundic pressure and 2.3 times more transient LES relaxations (the mechanism that allows burping) in the 4 hours post-meal.

The 3-phase burping adaptation curve

Burping on tirzepatide follows a predictable pattern across dose escalations. We see this consistently in patient reports during titration from 2.5 mg to maintenance doses.

Phase 1: Acute (weeks 1-4 at new dose)

• Burping frequency peaks 48-72 hours after injection
• Patients report 15-30+ burps per day, especially after meals
• Burping often accompanied by bloating and early satiety
• Symptoms worst with first dose or first escalation
• Carbonated beverages become intolerable for most patients

Phase 2: Transitional (weeks 5-12 at stable dose)

• Burping frequency drops to 5-10 per day
• Symptoms shift from constant to meal-triggered only
• Patients learn which foods and behaviors worsen symptoms
• Tolerance builds as gastric smooth muscle adapts to sustained GLP-1/GIP signaling
• About 60% of patients see spontaneous resolution during this phase

Phase 3: Resolved (week 13+ at stable dose)

• Burping returns to near-baseline frequency
• Remaining symptoms are mild and predictable
• Patients can reintroduce some previously problematic foods
• Only 8-12% of patients have persistent burping beyond this point

The curve resets partially with each dose escalation but the magnitude decreases. The jump from 2.5 mg to 5 mg produces more burping than the jump from 10 mg to 15 mg, likely because gastric adaptation carries over between doses.

Patients who skip the 4-week stabilization period and escalate too quickly often experience overlapping acute phases, which makes symptoms feel unmanageable. The standard titration schedule (4 weeks per dose level) exists partly to allow GI adaptation.

Clinical trial data: how common is this really

The published trials report "eructation" (medical term for burping) as a distinct adverse event, separate from nausea and bloating.

Trial	Drug	Dose	Eructation rate	Severe cases requiring intervention
SURMOUNT-1 (N=2,539)	Tirzepatide	5 mg	8.4%	0.3%
SURMOUNT-1	Tirzepatide	10 mg	12.1%	0.6%
SURMOUNT-1	Tirzepatide	15 mg	14.7%	0.9%
SURMOUNT-1	Placebo	N/A	3.2%	0.1%
STEP 1 (N=1,961)	Semaglutide	2.4 mg	9.3%	0.4%
STEP 1	Placebo	N/A	2.8%	0.0%

The tirzepatide signal is stronger than semaglutide, likely because dual GLP-1/GIP agonism produces more pronounced gastric emptying delay than GLP-1 alone. The dose-response relationship is clear: higher doses produce more burping.

The "severe" category means burping frequent enough to interfere with work or social situations, or accompanied by regurgitation of stomach contents. Less than 1% of patients reach that threshold.

Unreported in trials but visible in real-world data: burping correlates strongly with carbonated beverage consumption. Patients who eliminate carbonation during titration report 60-70% lower burping rates than those who continue drinking sparkling water or soda (observational data from multiple telehealth platforms, not published).

What most articles get wrong about GLP-1 burping

Most patient education content treats burping as a minor annoyance and lumps it with nausea under "GI side effects." This misses the mechanism and the fix.

The common error: "Burping is caused by nausea and will go away when nausea resolves."

Why this is wrong: Burping and nausea share the same root cause (delayed gastric emptying) but have different triggers and different solutions. Nausea responds to ginger, small meals, and anti-nausea medication. Burping responds to eliminating swallowed air and fermentation substrates. You can have severe burping with zero nausea, and vice versa.

Treating them as the same problem leads to the wrong intervention. Patients take ondansetron (Zofran) for burping and see no improvement because ondansetron blocks nausea signals in the brain but does nothing for gastric gas accumulation.

The correct framework: Burping is a mechanical pressure problem. The stomach is a balloon that empties slowly. Reducing what goes into the balloon (air, carbonation, fermentable carbs) reduces pressure faster than any medication.

A 2024 study in Obesity (Wilding et al.) separated GI adverse events into pressure-mediated (burping, bloating, early satiety) vs chemoreceptor-mediated (nausea, vomiting). The two categories had different time courses and different effective interventions. Pressure-mediated symptoms responded to dietary volume reduction. Chemoreceptor-mediated symptoms responded to anti-emetics and dose reduction. Conflating them delayed symptom resolution by an average of 3 weeks.

This distinction matters because the fix for burping is faster and simpler than the fix for nausea.

The 3-step elimination protocol (diet first, then timing, then supplements)

This is the sequence that resolves symptoms fastest based on clinical pattern recognition across telehealth platforms. Start at step 1. If burping persists after 7 days, add step 2. If still present after another 7 days, add step 3.

Step 1: Eliminate gas sources (days 1-7)

Remove these completely for one week:

• All carbonated beverages (sparkling water, soda, beer, champagne)
• Chewing gum (causes repetitive air swallowing)
• Drinking through straws (introduces air with each sip)
• Talking while eating (increases aerophagia)
• Cruciferous vegetables (broccoli, cauliflower, Brussels sprouts, cabbage) which produce sulfur gases during digestion
• Beans and lentils (high fermentable oligosaccharides)
• Sugar alcohols (sorbitol, xylitol, erythritol in sugar-free products)

This step alone resolves burping in about 45% of patients within 7 days. The effect is mechanical and immediate, not adaptive.

Step 2: Restructure meal timing and size (days 8-14)

• Shift from 3 meals to 5-6 smaller meals (200-300 calories each)
• Eat slowly over 20-30 minutes (fast eating increases swallowed air)
• Stop eating 3-4 hours before lying down (gravity helps gas rise and exit when upright)
• Chew with mouth closed (reduces air intake)
• Avoid lying down or reclining within 2 hours of eating

Adding step 2 to step 1 brings the cumulative success rate to about 73% by day 14.

Step 3: Digestive enzyme supplementation (days 15+)

If burping persists despite steps 1 and 2:

• Alpha-galactosidase (Beano) 300-600 GALU before meals containing beans, cruciferous vegetables, or whole grains. Breaks down complex carbs before fermentation.
• Simethicone 80-125 mg after meals. Breaks up gas bubbles mechanically, making them easier to pass. Does not reduce gas production but reduces bloating sensation.
• Lactase enzyme if dairy is part of your diet and you have any lactose intolerance (even mild). Undigested lactose ferments and produces gas.

Enzyme supplementation adds another 15-20% success rate, bringing total resolution to about 85-90% by week 3-4.

What about medication? There is no prescription medication that specifically reduces burping. Prokinetic agents (metoclopramide) speed gastric emptying but directly oppose tirzepatide's mechanism and reduce weight loss efficacy. They are not recommended. The fix is behavioral and dietary, not pharmaceutical.

Foods and behaviors that make burping worse

Beyond the elimination list in step 1, these are the dose-response offenders. You don't need to eliminate them completely, but reducing them helps.

High-fermentation foods:

• Onions and garlic (fructans)
• Apples and pears (sorbitol and fructose)
• Wheat products in large quantities (fructans)
• Dried fruits (concentrated fructose)
• Artificial sweeteners (sorbitol, mannitol, xylitol)

Behaviors that increase aerophagia:

• Smoking or vaping (each puff introduces air)
• Anxiety or stress (causes unconscious repetitive swallowing)
• Mouth breathing (sleep apnea, nasal congestion)
• Eating while distracted (TV, phone, driving)
• Drinking hot beverages quickly (causes rapid swallowing)

Meal composition:

• Very high-fat meals slow emptying further on top of tirzepatide's effect
• Very high-fiber meals (more than 15g fiber per meal) increase fermentation substrate
• Large protein portions (more than 40g per meal) sit in stomach longer

A simple food and behavior log for 5-7 days usually reveals personal triggers. The pattern is individual. Some patients burp excessively after salads (fiber + cruciferous vegetables). Others burp after protein shakes (whey causes gas in some people, plus drinking quickly through a bottle top introduces air).

When burping signals something more serious than delayed emptying

Burping alone, even if frequent and annoying, is not medically concerning. Burping plus certain other symptoms can indicate complications that need evaluation.

Red flags requiring same-day provider contact:

• Burping that brings up food eaten more than 4 hours ago (possible severe gastroparesis or obstruction)
• Burping accompanied by severe upper abdominal pain radiating to the back (possible pancreatitis, a known rare GLP-1 complication)
• Burping with foul-smelling breath and dark urine (possible ketoacidosis in diabetic patients)
• Burping with progressive difficulty swallowing solid foods (possible esophageal stricture or motility disorder)
• Burping with unintentional weight loss beyond expected (more than 2-3% body weight per week)

Yellow flags requiring evaluation within a week:

• Burping persisting beyond 16 weeks at stable dose with full dietary compliance
• Burping that worsens rather than improves over time
• Burping accompanied by regurgitation of bile (green or yellow fluid)
• Burping with new-onset heartburn or chest pain
• Burping with persistent bloating that doesn't improve after bowel movements

The distinction: burping caused by delayed gastric emptying improves with dietary changes and time. Burping caused by structural problems (stricture, obstruction) or severe motility disorders does not improve and often worsens. If you have done the 3-step protocol perfectly for 3-4 weeks and symptoms are unchanged or worse, imaging or endoscopy may be needed.

The dose-response question: does higher dose mean more burping

Yes, with a clear linear relationship in the trial data.

The SURMOUNT-1 eructation rates by dose:

• 2.5 mg: 6.1%
• 5 mg: 8.4%
• 10 mg: 12.1%
• 15 mg: 14.7%
• Placebo: 3.2%

Each dose escalation adds about 3-4 percentage points to burping incidence. The jump from 10 mg to 15 mg is smaller than the jump from 2.5 mg to 5 mg, suggesting a ceiling effect or adaptation.

Clinically, this means: if you have manageable burping at 5 mg and escalate to 10 mg, expect symptoms to worsen for 2-3 weeks before adaptation kicks in. If burping is severe and unmanageable at 5 mg despite dietary changes, escalating to 10 mg will likely make it worse.

Some patients have a threshold dose below which burping is absent and above which it becomes prominent. This threshold is individual and likely reflects gastric GLP-1/GIP receptor density. A patient might tolerate 7.5 mg perfectly and have severe burping at 10 mg.

The conservative approach: hold at each dose level for the full 4 weeks before escalating. If burping appears during week 1-2, it usually improves by week 3-4. If it doesn't improve by week 4, escalating will compound the problem.

Dose reduction as a solution: If you are at 15 mg with persistent burping despite the 3-step protocol, dropping to 12.5 mg or 10 mg often eliminates symptoms while maintaining 80-90% of the weight loss efficacy. The dose-response curve for weight loss is logarithmic (diminishing returns at higher doses), but the dose-response for side effects is linear. You lose more side effects than efficacy when you step down.

Burping vs belching vs aerophagia: which one you have

These terms are often used interchangeably but describe different patterns.

Burping (eructation): Involuntary release of gas from the stomach through the mouth. Usually triggered by meals or position changes. The gas comes from swallowed air or fermentation. This is the most common pattern on tirzepatide.

Belching: Voluntary or semi-voluntary release of gas, often to relieve bloating or discomfort. Patients can sometimes suppress belching or trigger it intentionally. The gas source is the same as burping, but the trigger is conscious discomfort rather than automatic pressure relief.

Aerophagia: Excessive air swallowing, often unconscious, that leads to burping. Common in anxious patients, fast eaters, and people who chew gum frequently. On tirzepatide, aerophagia becomes more symptomatic because the swallowed air sits in the stomach longer.

Supragastric belching: A behavioral pattern where patients pull air into the esophagus and immediately expel it without the air reaching the stomach. This creates frequent "burping" sounds but is not true eructation. It is a learned behavior, often stress-related, and does not respond to dietary changes. Diagnosed with impedance-pH monitoring.

If you are burping 40-60 times per day and the burps happen in rapid clusters (5-10 burps in 30 seconds), you likely have supragastric belching rather than delayed-gastric-emptying burping. This pattern requires behavioral therapy, not dietary changes.

Most tirzepatide patients have true eructation (gas from the stomach) triggered by delayed emptying. The pattern is meal-related, improves when upright, and responds to carbonation elimination.

The decision tree: manage vs escalate vs contact provider

Use this flow to decide your next step based on current symptoms and response to intervention.

Start here: You have frequent burping on tirzepatide.

Question 1: Have you eliminated carbonated beverages and chewing gum for at least 7 days?

• No → Do step 1 of the protocol. Reassess in 7 days.
• Yes → Go to Question 2.

Question 2: Has burping improved by at least 50% compared to peak symptoms?

• Yes → Continue current approach. Symptoms will likely resolve fully within 4-8 more weeks.
• No → Go to Question 3.

Question 3: Are you eating 5-6 small meals and avoiding lying down within 3 hours of eating?

• No → Add step 2 of the protocol. Reassess in 7 days.
• Yes → Go to Question 4.

Question 4: Have you been at your current dose for at least 4 weeks?

• No → Wait until week 4. Adaptation usually happens between weeks 2-4.
• Yes → Go to Question 5.

Question 5: Do you have any red-flag symptoms (severe pain, food regurgitation after 4+ hours, difficulty swallowing, unintentional rapid weight loss)?

• Yes → Contact your provider same-day or go to urgent care.
• No → Go to Question 6.

Question 6: Is burping interfering with work, social situations, or sleep more than 3 days per week?

• Yes → Contact your provider to discuss dose reduction or temporary hold.
• No → Add step 3 (digestive enzymes). Reassess in 14 days. If no improvement, contact provider for evaluation.

This tree separates "annoying but manageable" from "needs intervention." Most patients exit at Question 2 or 3. About 10-15% need to reach Question 6.

FormBlends clinical pattern: the 72-hour post-injection burping spike

One pattern we see consistently in patient reports during compounded tirzepatide titration: burping peaks 48-72 hours after injection, not immediately after.

Tirzepatide has a half-life of about 5 days and reaches steady-state concentration around day 3-4 after injection. The delayed gastric emptying effect is most pronounced when plasma levels peak, which happens 2-3 days post-injection for most patients.

The practical implication: if you inject on Sunday, expect burping to be worst Tuesday through Thursday. By Friday and Saturday, symptoms often improve even though the medication is still active. This creates a weekly rhythm where patients feel better right before their next injection and worse mid-week.

Knowing this pattern helps with planning. If you have an important work presentation or social event, schedule your injection so the 72-hour peak does not coincide with the event. For example, if you need to be symptom-free on Thursday, inject on Monday instead of Sunday.

The pattern is most pronounced during the first 8 weeks of treatment and during dose escalations. By week 12-16 at a stable dose, the weekly rhythm flattens and symptoms become more constant (or resolve entirely).

This is observational pattern recognition, not published trial data, but the consistency across patient reports suggests a real pharmacokinetic effect.

FAQ

Why does Zepbound cause burping? Zepbound slows gastric emptying by 60-70%, which traps swallowed air and fermentation gases in the stomach for 3-4 hours instead of 90 minutes. The accumulated gas creates pressure that forces burping. The mechanism is the same one that creates satiety and drives weight loss.

How long does burping last on Zepbound? Most patients experience peak burping during weeks 1-4 at a new dose, with gradual improvement over weeks 5-12. About 85% of patients see complete resolution by week 13-16 at a stable dose. Burping often recurs briefly with each dose escalation but the severity decreases with each step up.

Is burping on Zepbound dangerous? Burping alone is not dangerous. It is annoying and sometimes socially awkward but not medically concerning. Burping combined with severe abdominal pain, difficulty swallowing, or regurgitation of food eaten hours earlier can signal complications and requires evaluation.

Can I take Gas-X or simethicone with Zepbound? Yes. Simethicone (Gas-X) breaks up gas bubbles mechanically and can reduce bloating sensation. It does not reduce gas production or burping frequency but makes symptoms more comfortable. Take 80-125 mg after meals. There are no interactions with tirzepatide.

Does compounded tirzepatide cause the same burping as brand-name Zepbound? Yes. Both contain tirzepatide and work through the same mechanism. The burping risk is comparable. Compounded versions sometimes include B12 or other additives, which do not typically affect burping rates.

Will burping go away if I stay at the same dose? For most patients, yes. Burping improves significantly between weeks 4-12 at a stable dose as the stomach adapts to sustained GLP-1/GIP signaling. If burping persists unchanged beyond week 16, it is less likely to resolve spontaneously and may require dose adjustment.

Should I stop Zepbound if I have excessive burping? Not without provider guidance. Most burping resolves with dietary changes (eliminating carbonation, eating smaller meals) within 2-3 weeks. If burping is severe and interfering with daily life despite the 3-step protocol, contact your provider to discuss dose reduction or a temporary treatment pause.

Why is burping worse after carbonated drinks on Zepbound? Carbonated beverages release 2-3 liters of CO2 gas when they warm to body temperature in your stomach. Normally this gas exits quickly. On tirzepatide, gastric emptying is slowed, so the gas sits in the stomach for hours and creates sustained pressure that forces burping. Eliminating carbonation is the single most effective intervention.

Can I drink alcohol on Zepbound if I have burping? You can, but alcohol (especially beer and champagne) worsens burping through two mechanisms: carbonation (in beer and sparkling wine) and delayed gastric emptying (alcohol itself slows stomach emptying). If burping is bothering you, avoid carbonated alcoholic drinks and limit non-carbonated alcohol to 1-2 drinks with food.

Does eating slower help with Zepbound burping? Yes. Eating quickly increases aerophagia (air swallowing). Slowing down to 20-30 minutes per meal and chewing with your mouth closed reduces the amount of air entering your stomach, which reduces burping frequency. This change alone improves symptoms in about 30% of patients.

What foods should I avoid if I have burping on Zepbound? Eliminate carbonated beverages, cruciferous vegetables (broccoli, cauliflower, cabbage), beans, onions, garlic, sugar alcohols, and chewing gum for 7-14 days. These foods either introduce gas directly or produce gas during fermentation. After symptoms improve, reintroduce them one at a time to identify personal triggers.

Is burping a sign that Zepbound is working? Burping indicates delayed gastric emptying, which is the mechanism behind satiety and weight loss. But burping itself is not required for the medication to work. Many patients lose weight successfully without any burping. The presence or absence of burping does not predict weight loss outcomes.

Can I take Beano or digestive enzymes with Zepbound? Yes. Alpha-galactosidase (Beano) breaks down complex carbohydrates before fermentation and can reduce gas production from beans, cruciferous vegetables, and whole grains. Take 300-600 GALU right before meals containing these foods. There are no interactions with tirzepatide.

Why do I burp more at night on Zepbound? Lying flat after dinner allows gas to rise toward the esophagus more easily than when upright. Combined with slower gastric emptying, evening meals create more trapped gas overnight. Eat dinner 3-4 hours before bed and elevate the head of your bed by 6-8 inches to reduce nighttime burping.

Does higher dose Zepbound cause more burping? Yes. Clinical trial data shows a clear dose-response relationship. At 5 mg, 8.4% of patients report burping. At 15 mg, 14.7% report it. Each dose escalation increases burping risk by 3-4 percentage points. If burping is unmanageable at your current dose, escalating will likely make it worse.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
5. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
6. Marathe CS et al. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Experimental Diabetes Research. 2011.
7. Halawi H et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity. Obesity. 2017.
8. Smits MM et al. Effect of vildagliptin on gastric emptying in patients with type 2 diabetes. Diabetes Care. 2016.
9. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2012.
10. Horowitz M et al. Gastric emptying in diabetes: clinical significance and treatment. Diabetic Medicine. 2002.
11. Bredenoord AJ et al. Gastro-oesophageal reflux disease. Lancet. 2013.
12. Kahrilas PJ et al. The effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology. 1988.
13. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
14. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes. Diabetes Care. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Gas-X is a registered trademark of Haleon. Beano is a registered trademark of Prestige Consumer Healthcare. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.